UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines

Oral oncology, 2013-09, Vol.49 (9), p.872-877

2013

Volltextzugriff (PDF)

Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy

Annals of oncology, 2011-08, Vol.22 (8), p.1748-1754

2011

Volltextzugriff (PDF)

1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy

European journal of cancer (1990), 2015-09, Vol.51, p.S295-S296

2015

Volltextzugriff (PDF)

58: Proffered Paper: Noninvasive monitoring of tumour mutations and dynamics in circulating DNA of non-small cell lung cancer patients treated with EGFR inhibitors

European journal of cancer (1990), 2014-07, Vol.50, p.S14-S15

2014

Volltextzugriff (PDF)

EP17.04-03 Lung Cancer Care in Singapore: A review of the Healthcare Registry, 2013-2020

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S740

2023

Volltextzugriff (PDF)

6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)

European journal of cancer (1990), 2011, Vol.47, p.S470-S471

2011

Volltextzugriff (PDF)

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Annals of oncology, 2015-05, Vol.26 (5), p.998-1005

2015

Volltextzugriff (PDF)

P2.11A.11 Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S256-S257

2024

Volltextzugriff (PDF)

EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S391

2022

Volltextzugriff (PDF)

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S577-S577

2021

Volltextzugriff (PDF)

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S309-S310

2023

Volltextzugriff (PDF)

P1.23-03 Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S256

2023

Volltextzugriff (PDF)

Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience

Annals of oncology, 2019-11, Vol.30, p.ix165-ix166

2019

Volltextzugriff (PDF)

355O Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI)

Annals of oncology, 2023-11, Vol.34, p.S1608

2023

Volltextzugriff (PDF)

PL04.03 Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S4-S4

2024

Volltextzugriff (PDF)

PP01.74 Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e42-e42

2023

Volltextzugriff (PDF)

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2016-12, Vol.27 (12), p.2210-2215

2016

Volltextzugriff (PDF)

40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies

Annals of oncology, 2021-03, Vol.32, p.S17-S17

2021

Volltextzugriff (PDF)

1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials

Annals of oncology, 2021-09, Vol.32, p.S1241-S1241

2021

Volltextzugriff (PDF)

631 Mislocalization of the apoptosome protein Apaf-1 is a strong marker of drug resistance in B cell lymphomas

European journal of cancer supplements, 2010, Vol.8 (7), p.198-198

2010

Volltextzugriff (PDF)

Biophysical cues enhance myogenesis of human adipose derived stem/stromal cells

Biochemical and biophysical research communications, 2013-08, Vol.438 (1), p.180-185

2013

Volltextzugriff (PDF)

P28.01 Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1044-S1044

2021

Volltextzugriff (PDF)

Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients

Breast cancer research and treatment, 2014-02, Vol.144 (1), p.143-152

2014

Volltextzugriff (PDF)

515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Annals of oncology, 2021-09, Vol.32, p.S585-S586

2021

Volltextzugriff (PDF)

Phase I investigator’s perceptions to ‘supersized seamless trials in oncology

Annals of oncology, 2018-11, Vol.29, p.ix26-ix26

2018

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Englisch
(114)

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(27)
Humans
(23)
Technology
(20)
Engineering
(17)
Female
(15)
Male
(15)
Adult
(13)
Middle Aged
(13)
Oncology
(13)
Engineering, Chemical
(11)
Physical Sciences
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(9)
Aged
(8)
Chemistry
(8)
Hematology, Oncology And Palliative Medicine
(8)
Exact Sciences And Technology
(7)
Ultrafiltration
(7)
Applied Sciences
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines

Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy

1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy

58: Proffered Paper: Noninvasive monitoring of tumour mutations and dynamics in circulating DNA of non-small cell lung cancer patients treated with EGFR inhibitors

EP17.04-03 Lung Cancer Care in Singapore: A review of the Healthcare Registry, 2013-2020

6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma – a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

P2.11A.11 Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor

EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

P1.23-03 Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience

355O Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI)

PL04.03 Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

PP01.74 Clinical Validation of a Promising New Amplicon-Based Liquid Biopsy Platform for Detection of Guideline Recommended Biomarkers in Metastatic NSCLC

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

40P Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies

1835P Clinical outcome and prognostic factors for Asian patients in phase I clinical trials

631 Mislocalization of the apoptosome protein Apaf-1 is a strong marker of drug resistance in B cell lymphomas

Biophysical cues enhance myogenesis of human adipose derived stem/stromal cells

P28.01 Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC

Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients

515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Phase I investigator’s perceptions to ‘supersized seamless trials in oncology

Suchergebnisse filtern